Search results for "Positron"

showing 10 items of 1346 documents

Expectation of sensory stimulation modulates brain activation during visual motion stimulation.

2005

The differential effects of visual hemifield motion stimulation during fixation of a stationary target were compared under two conditions: fixation straight ahead without any further instructions and fixation straight ahead with attention shifted to the "dark hemifield." Data from nine right-handed volunteers revealed that striate and extrastriate right hemispheric visual areas exhibited larger activations during left hemifield motion stimulation when attention was shifted to the right dark hemifield. Montreal Neurological Institute (MNI) coordinates (26, -98, -4) of the additional clusters activated in the latter condition corresponded best to the kinetic occipital region, which is known t…

Brain activationAdultMalegenetic structuresModels NeurologicalMotion PerceptionStimulationFixation OcularNeural populationGeneral Biochemistry Genetics and Molecular BiologyFunctional LateralityHistory and Philosophy of ScienceReference ValuesPhysical StimulationHumansMotion perceptionCommunicationBrain MappingSensory stimulation therapybusiness.industryGeneral NeuroscienceBrainMiddle AgedVisual motionStraight aheadPositron-Emission TomographyFixation (visual)Visual PerceptionFemaleVisual FieldsPsychologybusinessNeurosciencePhotic StimulationAnnals of the New York Academy of Sciences
researchProduct

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes

2012

BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was m…

CA15-3Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorStandardized uptake valueAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineProgesterone receptormedicineHumansskin and connective tissue diseasesPathologicalComputingMilieux_MISCELLANEOUSChemotherapybusiness.industryHematologyMetabolismmedicine.disease3. Good healthOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessTomography X-Ray Computed
researchProduct

Measurement and interpretation of the $W$-pair cross-section in $e^+e^-$ interactions at 161 GeV

1997

In 1996 LEP ran at a centre-of-mass energy of 161~GeV, just above the threshold of W-pair production. DELPHI accumulated data corresponding to an integrated luminosity of $9.93 {\mathrm{~pb^{-1}}}$, and observed 29 events that are considered as candidates for W-pair production. From these, a cross-section for the doubly resonant $e^+e^-\to\mathrm{WW}$ process of $3.67~^{+0.97}_{-0.85} \pm 0.19{\mathrm{~pb}}$ has been measured. Within the Standard Model, this cross-section corresponds to a mass of the W-boson of ${\mathrm{80.40~\pm~0.44~(stat.)~\pm~0.09~(syst.) ~\pm 0.03~(LEP)~GeV}}/c^2$. Alternatively, if $m_{\mathrm{W}}$ is held fixed at its current value determined by other experiments, t…

COLLISIONSNuclear and High Energy PhysicsParticle physicsElectron–positron annihilation01 natural sciencesBOSON MASS; ROOT-S=1.8 TEV; COLLISIONS; COUPLINGSPartícules (Física nuclear)Standard ModelInterpretation (model theory)Nuclear physics0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsDetectors de radiacióDELPHIPhysicsLuminosity (scattering theory)010308 nuclear & particles physicsROOT-S=1.8 TEVCOUPLINGSLARGE ELECTRON POSITRON COLLIDERBOSON MASSCross section (geometry)PARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIPARTICLE PHYSICSHigh Energy Physics::ExperimentParticle Physics - ExperimentPhysics Letters B
researchProduct

Measurement of the lifetime of tau-lepton

1996

The tau lepton lifetime is measured with the L3 detector at LEP using the complete data taken at centre-of-mass energies around the Z pole resulting in tau_tau = 293.2 +/- 2.0 (stat) +/- 1.5 (syst) fs. The comparison of this result with the muon lifetime supports lepton universality of the weak charged current at the level of six per mille. Assuming lepton universality, the value of the strong coupling constant, alpha_s is found to be alpha_s(m_tau^2) = 0.319 +/- 0.015(exp.) +/- 0.014 (theory). The tau lepton lifetime is measured with the L3 detector at LEP using the complete data taken at centre-of-mass energies around the Z pole resulting in τ τ =293.2 ± 2.0 (stat) ± 1.5 (syst) fs . The c…

COLLISIONSNuclear and High Energy PhysicsParticle physicsLUND MONTE-CARLOPAIR PRODUCTIONElectron–positron annihilationFOS: Physical sciencesElementary particleddc:500.201 natural sciences7. Clean energyResonance (particle physics)JET FRAGMENTATIONDECAYSHigh Energy Physics - ExperimentNuclear physicsParticle decayHigh Energy Physics - Experiment (hep-ex)0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]SILICON MICROVERTEX DETECTORPRECISE MEASUREMENTLimit (mathematics)QCD ANALYSIS010306 general physicsL3 EXPERIMENTCoupling constantPhysicsMuonAnnihilationTEST BEAME+E-PHYSICS010308 nuclear & particles physicsALPHA(S)High Energy Physics::PhenomenologyDetectorPair productionSPECTRAL FUNCTIONSComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHigh Energy Physics::ExperimentParticle Physics - ExperimentLeptonNuclear and Particle Physics Proceedings
researchProduct

Search for neutral heavy leptons produced in Z decays

1997

Weak isosinglet Neutral Heavy Leptons ($\nu_m$) have been searched for using data collected by the DELPHI detector corresponding to $3.3\times 10^{6}$ hadronic~Z$^{0}$ decays at LEP1. Four separate searches have been performed, for short-lived $\nu_m$ production giving monojet or acollinear jet topologies, and for long-lived $\nu_m$ giving detectable secondary vertices or calorimeter clusters. No indication of the existence of these particles has been found, leading to an upper limit for the branching ratio $BR($Z$^0\rightarrow \nu_m \overline{\nu})$ of about $1.3\times10^{-6}$ at 95\% confidence level for $\nu_m$ masses between 3.5 and 50 GeV/$c^2$. Outside this range the limit weakens rap…

COLLISIONSParticle physicsE+E ANNIHILATIONPhysics and Astronomy (miscellaneous)Electron–positron annihilationHadronMASSJet (particle physics)HIGH-ENERGY-PHYSICS; MONOJET PRODUCTION; E+E ANNIHILATION; MONTE-CARLO; BOSON; LIMITS; MASS; LEP; PERFORMANCE; COLLISIONSHIGH-ENERGY-PHYSICS01 natural sciences7. Clean energyMONOJET PRODUCTIONNuclear physicsLIMITSMONTE-CARLO0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]010306 general physicsDELPHIBosonPhysics010308 nuclear & particles physicsBranching fractionHigh Energy Physics::PhenomenologyBOSONLEPPERFORMANCELARGE ELECTRON POSITRON COLLIDERPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHILarge Electron–Positron ColliderPARTICLE PHYSICSHigh Energy Physics::ExperimentNeutrinoParticle Physics - ExperimentLepton
researchProduct

Charged particle multiplicity distributions in restricted rapidity intervals in Z0 hadronic decays.

1991

The multiplicity distributions of charged particles in restricted rapidity intervals in Z0 hadronic decays measured by the DELPHI detector are presented. The data reveal a shoulder structure, best visible for intervals of intermediate size, i.e. for rapidity limits around ±1.5. The whole set of distributions including the shoulder structure is reproduced by the Lund Parton Shower model. The structure is found to be due to important contributions from 3-and 4-jet events with a hard gluon jet. A different model, based on the concept of independently produced groups of particles, "clans", fluctuating both in number per event and particle content per clan, has also been used to analyse the pres…

COLLISIONSParticle physicsE+E ANNIHILATIONPhysics and Astronomy (miscellaneous)LUND MONTE-CARLOElectron–positron annihilationHadronElementary particlePETRA ENERGIES01 natural sciences250 GEV/CNuclear physicsDEPENDENCE0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]RapidityNuclear Experiment010306 general physicsParton showerEngineering (miscellaneous)LUND MONTE-CARLO; JET PRODUCTION-RATES; E+E ANNIHILATION; 250 GEV/C; PETRA ENERGIES; COLLISIONS; DEPENDENCE; FRAGMENTATION; QCD; RESONANCEPhysics010308 nuclear & particles physicsJET PRODUCTION-RATESMultiplicity (mathematics)RESONANCEQCDCharged particleGluonPhysique des particules élémentairesHigh Energy Physics::ExperimentFRAGMENTATIONParticle Physics - Experiment
researchProduct

Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by …

2013

The fatty acids, n-butyric acid (BA), 4-phenylbutyric acid (PBA) and valproic acid (VPA, 2-propylpentanoic acid) have been used for many years in the treatment of a variety of CNS and peripheral organ diseases including cancer. New information that these drugs alter epigenetic processes through their inhibition of histone deacetylases (HDACs) has renewed interest in their biodistribution and pharmacokinetics and the relationship of these properties to their therapeutic and side effect profiles. In order to determine the pharmacokinetics and biodistribution of these drugs in primates, we synthesized their carbon-11 labeled analogues and performed dynamic positron emission tomography (PET) in…

Cancer ResearchBiodistributionSide effectPharmacologyPhenylbutyrateArticleButyric acidchemistry.chemical_compoundPharmacokineticsmedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionCarbon RadioisotopesValproic AcidRadiochemistryValproic AcidBrainLipid metabolismBlood ProteinsBlood proteinsPhenylbutyratesHistone Deacetylase InhibitorschemistryIsotope LabelingPositron-Emission TomographyMolecular MedicineButyric AcidFemalemedicine.drugPapio
researchProduct

Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOC.

2008

Abstract Introduction Imaging of somatostatin receptor expressing tumours has been greatly enhanced by the use of 68 Ga-DOTATOC and PET/CT. Methods In this work, a purification method for the 68 Ge/ 68 Ga generator eluate and a method to produce 68 Ga-DOTATOC suitable for clinical use were evaluated. The generator eluate was purified and concentrated on a cation-exchange cartridge in HCl/acetone media. The efficacy of this procedure in eliminating metal impurities from the 68 Ga solution was investigated by ICP-MS. The radiotracer quality was evaluated by radio-TLC, GC and γ-ray spectrometry. Results 68 Ga-DOTATOC preparations ( n =33) were carried out with a mean synthesis yield of 59.3±2.…

Cancer ResearchGenerator (computer programming)ChromatographyElutionIon chromatographyGallium RadioisotopesMass spectrometryOctreotide68ga dotatocchemistry.chemical_compoundchemistryYield (chemistry)Isotope LabelingPositron-Emission TomographyAcetoneOrganometallic CompoundsMolecular MedicineRadiology Nuclear Medicine and imagingPurification methodsClinical MedicineRadiopharmaceuticalsNuclear medicine and biology
researchProduct

Reinvestigation of the synthesis and evaluation of [N-methyl-11C]vorozole, a radiotracer targeting cytochrome P450 aromatase

2009

Abstract Introduction We reinvestigated the synthesis of [ N -methyl- 11 C]vorozole, a radiotracer for aromatase, and discovered the presence of an N -methyl isomer which was not removed in the original purification method. Herein we report the preparation and positron emission tomography (PET) studies of pure [ N -methyl- 11 C]vorozole. Methods Norvorozole was alkylated with [ 11 C]methyl iodide as previously described and also with unlabeled methyl iodide. A high-performance liquid chromatography (HPLC) method was developed to separate the regioisomers. Nuclear magnetic resonance (NMR) spectroscopy ( 13 C and 2D-nuclear Overhauser effect spectroscopy NMR) was used to identify and assign s…

Cancer ResearchMagnetic Resonance SpectroscopyTime FactorsAlkylationStereochemistryStereoisomerismNuclear Overhauser effectAlkylationHigh-performance liquid chromatographyArticlechemistry.chemical_compoundAromatasemedicineStructural isomerAnimalsRadiology Nuclear Medicine and imagingHydrocarbons IodinatedRadioactive TracersChromatography High Pressure LiquidChemistryBrainStereoisomerismNuclear magnetic resonance spectroscopyTriazolesPositron-Emission TomographyVorozoleMolecular MedicineFemalePapiomedicine.drugMethyl iodideNuclear Medicine and Biology
researchProduct

Nanofitins targeting heat shock protein 110: an innovative immunotherapeutic modality in cancer.

2021

The presence of an inactivating heat shock protein 110 (HSP110) mutation in colorectal cancers has been correlated with an excellent prognosis and with the ability of HSP110 to favor the formation of tolerogenic (M2-like) macrophages. These clinical and experimental results suggest a potentially powerful new strategy against colorectal cancer: the inhibition of HSP110. In this work, as an alternative to neutralizing antibodies, Nanofitins (scaffold ~7 kDa proteins) targeting HSP110 were isolated from the screening of a synthetic Nanofitin library, and their capacity to bind (immunoprecipitation, biolayer interferometry) and to inhibit HSP110 was analyzed in vitro and in vivo. Three Nanofiti…

Cancer ResearchMice03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemPeptide LibraryIn vivoCell Line TumorHeat shock proteinTumor MicroenvironmentmedicineAnimalsHumansCytotoxic T cellHSP110 Heat-Shock Proteinssmall peptide moleculesTumor microenvironmentanticancer targeted therapybiologyChemistryMacrophagesCancer[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesmedicine.diseaseXenograft Model Antitumor AssaysPeptide FragmentsIn vitro3. Good healthNanofitinsOncologyPositron-Emission Tomography030220 oncology & carcinogenesisbiology.proteinCancer researchFemaleAntibodyColorectal NeoplasmsHSP110
researchProduct